Evidence map›Paper›PMID 40056158›Full record

Trial reportNeuro-oncology2025

High-precision radiotherapy achieves excellent long-term control and preserves function in pediatric craniopharyngioma-Subset analysis of a randomized trial.

Rakesh Jalali, Suman Ghosh, Abhishek Chatterjee, Savita Goswami, Nalini Shah, Debnarayan Dutta, Uday Krishna, Tejpal Gupta, Jayant S Goda

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00517959 (Efficacy of Stereotactic Conformal Radiotherapy), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00517959 phase3unknown statusnot on this map

Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial

TypeinterventionalSponsorTata Memorial HospitalRan2001 to 2017Enrolled200ConditionsLow Grade Gliomas, Craniopharyngioma, Ependymomas, MeningiomasArmsStereotactic Conformal radiotherapy, Conventional radiotherapy
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rakesh JalaliNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-0318-5536
Suman GhoshNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.ORCID 0009-0004-2585-1650
Abhishek ChatterjeeNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
Savita GoswamiNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
Nalini ShahNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0002-2295-0475
Debnarayan DuttaNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
Uday KrishnaNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.
Tejpal GuptaNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.ORCID 0000-0001-8256-9206
Jayant S GodaNeuro-Oncology Disease Management Group, Tata Memorial Centre and Homi Bhabha National Institute, Mumbai, India.

Funding

Tata Memorial Center
6 · The paper itself

Abstract

backgroundThe evolving treatment paradigm in children and adolescents with craniopharyngioma (CP) aims at minimizing late functional sequelae. Advanced radiotherapeutic techniques offer theoretical advantages of preserving neurological functions; however, clinical evidence of such is limited. The current study constitutes a secondary analysis of CP patients in a Randomized Control Trial testing Conventional RT (ConvRT) versus Stereotactic Conformal Radiotherapy (SCRT; NCT00517959).

methodsEighty-two patients of CP (SCRT: 39, ConvRT: 43, Dose: 54 Gy in 30 fractions) were analyzed, assessing the clinical impact of dosimetric sparing on neurocognitive function, endocrine function, overall survival (OS) and local control (LC). Patients were longitudinally assessed from baseline through 5 years post-treatment using the Weschler Intelligence Score Chart/WAIS scales.

resultsThe median age was 13 years (IQR = 9-17 years). The 10-year OS and LC rates were 86.4% and 92.7%, respectively, with no significant difference between the arms. SCRT patients showed significant improvement in mean full-scale IQ (difference in slope = 3.3 points per year, P = .01) and performance quotient (difference in slope = 3.6, P = .04) compared to those treated with ConvRT. Freedom from cognitive decline (a 5-point drop) at 5 years was higher with SCRT (66.6% vs. 38.2%; HR = 0.41, P = .03). Younger age (<15 years) was a significant negative predictor of neurocognitive outcomes (P = .002). SCRT patients also experienced a lower cumulative incidence of new neuroendocrine dysfunction (25.7% vs. 48.8%, P = .029).

conclusionsSCRT offers excellent tumor control and similar survival with superior long-term preservation of neurocognitive and endocrine functions in CP patients compared to conventional RT. High-precision RT should constitute the standard of care in CP.

Indexed as

CraniopharyngiomaPituitary NeoplasmsRadiosurgeryRadiotherapy, ConformalAdolescentChildFemaleFollow-Up StudiesHumansMalePrognosisSurvival RatecraniopharyngiomaendocrineneurocognitionSCRTtumor control

Identifiers

PMID40056158
PMCPMC12448793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.